Council on Certification
Home Contact Us Site
About Credential Exam Eligibility Resources

Sample Questions

Search CTR Exam Web Site



1. Which of the following information is the most important to record in the chemotherapy text field in a patient abstract?

Start DateFacility NameChemo AgentRoute Administration
D. N Y Y Y

2. The purpose of a re-abstracting study is to assess the accuracy of registry data against the

A. accession register B. suspense list
C. medical record D. casefinding reports

3. The Cancer Committee is reviewing causes for positive surgical margins on resected kidney tumors.  After generating a report on resected kidney tumors, which of the following is most appropriate to identify the possible causes?

A. Review the surgical procedure codes used. B. Obtain consent from surviving patients for the study.
C. Run a survival report on patients who had the surgery. D. Evaluate surgical complications from the resection.

4. A cancer registrar at Hospital A receives a request from another registry for information that is not needed to complete a cancer abstract. Which of the following should the registrar at Hospital A do?

A. Notify the privacy officer. B. State that the information cannot be shared.
C. Prepare the information for sharing. D. Consult with administration.

5. Quality control of registry data is a direct responsibility of the

A. pathologist B. tumor registrar
C. Cancer Committee D. physician advisor

6. When the central cancer registry compares coded information to text documentation, it is called
A. record consolidation B. patient lineage
C. inter-database checking D. visual editing


7. A patient has a history of BPH and has increasing urinary symptoms. His DRE was normal, and his PSA was slightly elevated. TURP was performed and revealed a focus of adenocarcinoma in the left lobe of the prostate. What FORDS surgical code should be assigned?

A. 20 B. 21
C. 22 D. 23

**There are 2 questions that refer to scenario below.**

The following information is available for a patient:
Malignant melanoma without ulceration, Clark's level III, depth of invasion 1.48 mm, in lentigo maligna, right arm. Regional lymph nodes are not involved. No distant metastases found.

8. What are the primary site and histology codes?

A. C44.6 M-8720/3 B. C44.6 M-8742/3
C. C76.4 M-8720/3 D. C76.4 M-8742/3

9. What is the pathologic T category???

A. T1a B. T2a
C. T2b D. TX

Home | About | Credential | Exam | Eligibility | Resources

Copyright © 2004-2016 by National Cancer Registrars Association,
all rights reserved.